CoChat
Sign Up
Cited by 28Gastrointestinal motility and disordersDiabetes Treatment and ManagementDiabetes Management and Research

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Liraglutide accelerates colonic transit in people with type 1 diabetes and polyneuropathy: A randomised, double‐blind, placebo‐controlled trial

Open access
Langmach Wegeberg, Anne‐Marie, Hansen, Christian Stevns, Farmer, Adam D, Karmisholt, Jesper Scott, Drewes, Asbjorn M, Jakobsen, Poul Erik, Brock, Birgitte, Brock, Christina·2020·United European Gastroenterology Journal
DOI 10.1177/2050640620925968PMC PMC7437086
Open this paper in CoChat — free accountOpen PDF

Abstract

Background: Glucagon‐like peptide‐1 receptor agonists, such as liraglutide, reduce hyperglycaemia and induce weight loss and are used as a treatment in diabetes. However, common adverse effects include nausea, loss of appetite and prolonged gastric emptying. It is not known whether these changes are centrally generated or if liraglutide alters the enteric motility. Objective: To investigate the effects of liraglutide on gastrointestinal function and symptoms. Methods: A total of 48 adults with type 1 diabetes and confirmed distal symmetric polyneuropathy were randomised to receive liraglutide 1.8 mg/day or placebo for 26 weeks. Regional transit times and motility indexes were assessed with a wireless motility capsule, whereas symptoms were evaluated using the validated gastroparesis cardinal symptom index. Results: Liraglutide treatment reduced large bowel transit time (31.7%, p = 0.04) and decreased motility index (6.1%, p = 0.04) compared to placebo, whereas the groups did not differ in gastric emptying or small‐bowel transit times. Liraglutide increased postprandial fullness with 29% (p = 0.01). Increased small bowel transit time was associated with decreased bloating (p = 0.008). Conclusion: Liraglutide accelerates large bowel transit and decreases motility index, which may indicate better coordination of propulsive motility. This potentially improves the function of the enteric nervous system, leading to normalised colonic function and positive effects in type 1 diabetes.

Overview

Integrity signals

Registry

Crossref · 10.1177/2050640620925968

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In patients with type 1 diabetes, liraglutide reduced colon transit time.

    “Also, in patients with type 1 diabetes, liraglutide reduced colon transit time (50).”

    From Safety of Semaglutide (2021) · cites this paper as [50]

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 29

  1. 10.1007/s00125-015-3831-1 · DOI
  2. 10.1159/000175836 · DOI
  3. 10.1111/j.1464-5491.2005.01567.x · DOI
  4. 10.1016/S2213-8587(15)00436-2 · DOI
  5. 10.2310/JIM.0b013e318279b7d6 · DOI
  6. 10.2337/dc14-1984 · DOI · Paper page
  7. 10.1111/dom.12247 · DOI
  8. 10.1016/S2468-1253(17)30285-6 · DOI · Paper page
  9. Brock C, 2019, Liraglutide treatment reduced interleukin‐6 in adults with type 1 diabetes but did not improve established autonomic or polyneuropathy, Br J Clin Pharmacol
  10. 10.1007/s10620-009-0899-9 · DOI
  11. 10.1111/j.1365-2036.2007.03564.x · DOI
  12. 10.1111/j.1365-2982.2007.01061.x · DOI
  13. Sangnes DA, 2019, Wireless motility capsule compared with gastric emptying scintigraphy in the assessment of diabetic gastroparesis, Neurogastroenterol Motil, 31, 77
  14. 10.1111/j.1365-2036.2009.04162.x · DOI
  15. 10.1111/j.1365-2362.1984.tb01206.x · DOI
  16. 10.1111/apt.14438 · DOI
  17. 10.1111/apt.13329 · DOI
  18. 10.1007/s00125-016-4199-6 · DOI
  19. 10.1111/nmo.13407 · DOI
  20. Gentilella R, 2019, Glucagon‐like peptide‐1 receptor agonists in type 2 diabetes treatment: Are they all the same?, Diabetes Metab Res Rev, 35, 1, 10.1002/dmrr.3070 · DOI
  21. 10.1016/S2468-1253(17)30285-6 · DOI · Paper page
  22. 10.1111/dme.13421 · DOI
  23. 10.1038/ijo.2012.208 · DOI
  24. 10.1677/joe.0.1560177 · DOI
  25. 10.1152/ajpgi.00076.2012 · DOI
  26. 10.1111/nmo.13562 · DOI
  27. Farmer AD, 2016, Type 1 diabetic patients with peripheral neuropathy have pan‐enteric prolongation of transit times and heightened cecal fermentation, Gastroenterol, 150, S214, 10.1016/S0016-5085(16)30795-8 · DOI
  28. 10.1016/S0167-0115(02)00095-2 · DOI
  29. 10.2337/dc13-0347 · DOI

Cited by

Sorted by citations

Metadata

Authors
Langmach Wegeberg, A., Hansen, C. S., Farmer, A. D., Karmisholt, J. S., Drewes, A. M., Jakobsen, P. E., Brock, B., & Brock, C.
Affiliations
  • Mech‐Sense Department of Gastroenterology and Hepatology Aalborg University Hospital Aalborg Denmark
  • Capital Region of Denmark (DK)
  • Queen Mary University of London (GB)
  • Aalborg University Hospital (DK)
  • Aarhus University Hospital (DK)
  • University of Copenhagen (DK)
Corresponding author
Brock, Christina
ORCID
Venue
United European Gastroenterology Journal
Publisher
Wiley
Published
2020-07
Volume
8
Issue
6
Pages
695-704
ISSN
  • 2050-6406 (ISSN-L)
  • 2050-6414
DOI
10.1177/2050640620925968
PMC
PMC7437086
OpenAlex
W3021395068
Cited by
28
References
7
Citations by year
2026: 5 · 2025: 5 · 2024: 10 · 2023: 2 · 2022: 3 · 2021: 3
FWCI
1.74
Type
journal article
Language
en
Open access
Licence
Locations
  • United European Gastroenterology Journal (publishedVersion)
  • PubMed Central (publishedVersion)
  • VBN Forskningsportal (Aalborg Universitet) (publishedVersion, other-oa)
  • PubMed (publishedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, other-oa)
Funders
  • Novo Nordisk
  • Aalborg Universitet
  • Novo Nordisk Scandinavia AS
  • Talent Programme, Aalborg University
  • Empowering Industry and Research (EIR), Northern Jutland
Topics
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
liraglutide, type 1 diabetes, diabetic polyneuropathy, colonic transit, motility index, GLP-1 receptor agonists, gastrointestinal motility, postprandial fullness, bloating, wireless motility capsule, enteric nervous system
MeSH terms
Glucagon-Like Peptide-1 Receptor, Liraglutide, Glucagon-Like Peptide-1 Receptor Agonists, Adult, Appetite, Diabetes Mellitus, Type 1, Diabetic Nephropathies, Double-Blind Method, Female, Gastric Emptying, Gastrointestinal Transit, Humans, Intestine, Small, Male, Middle Aged, Nausea, Placebos, Polyneuropathies, Prospective Studies, Stomach, Treatment Outcome, Enteric Nervous System, Postprandial Period

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review